Arteris, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Arteris develops and licenses semiconductor system IP, including on-chip interconnect technology and SoC integration software, and provides related support and services.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $12.9 million | $13.2 million; down 2% |
| Gross profit / margin | $11.5 million / 89% | $12.0 million / 91% |
| Operating loss | $9.1 million | $8.8 million |
| Net loss / diluted loss per share | $9.4 million / $0.25 | $9.0 million / $0.26 |
| Operating cash flow | $0.5 million provided | $8.4 million used |
- Licensing, support and maintenance revenue was $11.7 million, approximately flat year over year. Variable royalties fell 37% to $0.8 million; management attributed the decline to a temporary volume decrease at a large customer. Other revenue rose to $0.4 million, mainly due to professional-services timing.
- Operating expenses totaled $20.6 million, down 1%. R&D fell 5% to $10.8 million, partly due to French R&D grants; sales and marketing rose 9% to $5.5 million, mainly from employee costs and headcount. Stock-based compensation increased to $3.7 million from $3.0 million.
- Cash and cash equivalents were $26.1 million and short-term investments were $18.7 million at quarter-end, totaling $44.8 million. Including $8.6 million of long-term investments, cash and investments totaled $53.4 million. Management said available resources and expected product receipts should cover requirements for at least 12 months; additional financing may be needed if that assessment changes.
- Operating cash flow improved from the prior-year quarter, supported in part by a $3.4 million increase in deferred revenue and other working-capital movements. Investing cash flow was $11.9 million provided, primarily reflecting maturities of investments; financing cash flow was $0.04 million provided.
- Vendor financing liabilities were $3.1 million, including $2.0 million current; these arrangements carry an imputed 10% rate. Operating lease liabilities totaled $4.2 million. The filing reports no material noncancelable commitments beyond those disclosed.
- Current assets were $61.8 million versus current liabilities of $49.8 million. Deferred revenue totaled $60.1 million. Stockholders’ equity was $9.5 million, and accumulated deficit was $112.7 million.
Business indicators, outlook and risks
- Annual Contract Value was $53.5 million, up from $51.4 million a year earlier. The company reported 21 Confirmed Design Starts versus 22, and Remaining Performance Obligations of $74.7 million versus $57.3 million.
- Separately, the filing reports $73.6 million of non-cancelable contracted but unsatisfied or partially satisfied performance obligations; $36.9 million is expected to be recognized over the next 12 months. This measure includes certain customer commitments and is not the same as the company’s RPO metric.
- Management expects R&D expense to increase in absolute terms and as a percentage of revenue in the near term, while expecting that percentage to decline over the medium to longer term as products launch. No specific revenue or earnings guidance for the year is provided in the supplied filing text.
- Royalties depend on customer product shipments, which can follow design wins by years. The company also describes seasonal sales patterns, customer and revenue concentration, and exposure to semiconductor-cycle changes. One customer represented 14% of Q1 revenue; two customers represented 30% and 16% of receivables at quarter-end.
- International exposure is significant: 65.7% of Q1 revenue came from outside the U.S. and 30.5% from China. Management warns that U.S. export restrictions and geopolitical developments could delay customer projects or constrain licensing and support in China.
- Arteris is defending patent-infringement claims brought by Network System Technologies, LLC in Texas courts. Claim construction results were pending; the company cannot predict the outcome or estimate the ultimate impact and expects increased legal expenses. Potential consequences include defense costs, customer-related claims, and business disruption.
- The company reported a full valuation allowance against federal, state and certain foreign deferred tax assets. The Q1 income-tax provision was $0.4 million despite the pretax loss. Management reported disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether royalty revenue recovers after the temporary large-customer volume decline, and how customer shipments and design starts develop.
- Whether reported ACV and RPO convert into recognized revenue on the expected timetable, including the distinction between the $74.7 million RPO metric and $73.6 million of non-cancelable obligations.
- Cash consumption, investment maturities, and the assumptions supporting management’s at-least-12-month liquidity assessment.
- Developments, legal costs, and potential customer effects of the pending patent litigation.
- Changes in China-related revenue, customer concentration, export-control exposure, and stock-based compensation and share dilution.